PBF-999

DRUG2 trials

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Palobiofarma SL

Conditions

CancerHuntington's Disease

Phase 1

Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers

CompletedNCT02208934

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauHuntington's Disease

Start: 2014-09-30End: 2015-10-31Updated: 2016-03-08

Study of PBF-999 in Solid Tumour Advanced Cancer

CompletedNCT03786484

Palobiofarma SLCancer

Start: 2017-10-01End: 2022-06-30Updated: 2023-01-26